Back to News
Market Impact: 0.2
Ascletis Submits U.S. IND For Oral Obesity Candidate ASC39
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Ascletis Pharma submitted an Investigational New Drug application to the U.S. FDA for ASC39 oral tablets, a small-molecule selective amylin receptor agonist being developed to treat obesity. The text provides no further details on the application or clinical program.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- From Wall Street to Silicon Valley, Anthropic IPO poised to have massive 'trickle-down effect'
- Anthropic’s IPO filing shows explosive growth, risks and staggering costs
- Microsoft offers buyouts to nearly 30% of workforce in ongoing AI shift
- Elon Musk warns more than 200 AI cloud companies face ‘guppy-level death’ as the AI boom runs into a debt crisis
- Anthropic’s risk factors include the end of humanity, a feud with the Pentagon, and CEO Dario Amodei’s reputation
- Meta, SpaceX, Anthropic stoke the AI funding frenzy. What it means for our stocks